Form 8-K - Current report:
SEC Accession No. 0001493152-22-030257
Filing Date
2022-11-03
Accepted
2022-11-03 06:02:23
Documents
14
Period of Report
2022-11-03
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 39519
2 ex99-1.htm EX-99.1 19050
3 logo_001.jpg GRAPHIC 5681
  Complete submission text file 0001493152-22-030257.txt   252438

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lpcn-20221103.xsd EX-101.SCH 3227
5 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lpcn-20221103_lab.xml EX-101.LAB 34240
6 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lpcn-20221103_pre.xml EX-101.PRE 22359
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3605
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

IRS No.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36357 | Film No.: 221355968
SIC: 2834 Pharmaceutical Preparations